NCT04908202

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 670 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Conditions

• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	Deucravacitinib	Specified dose on specified days
OTHER	Placebo	Specified dose on specified days

Timeline

• Start date: 2021-07-13
• Primary completion: 2024-09-05
• Completion: 2027-06-10
• First posted: 2021-06-01
• Last updated: 2025-10-24
• Results posted: 2025-10-24

Locations

183 sites across 21 countries: United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Russia, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study